Sahin AR, Erdogan A. Novel Coronavirus (COVID-19) outbreak: a review of the current literature. EJMO 2020; 4(1): 1-7.
Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents 2020; 30(3): 269-71.
Kumar D, Malviya R, Kumar Sharma P. Corona Virus: A Review of COVID-19. EJMO 2020; 4(1): 8-25.
Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents 2020; 55105923
WHO Director-General opening remarks at the media briefing on
Mehta N, Mazer-Amirshahi M, Alkindi N. Pharmacotherapy in COVID -19. Narrative review. The American journal of emergency
Tang B, Li S, Xiong Y, et al. Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient. Kidney Medicine 2020.
Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2020.
Philippe G, Lagierac J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents 2020; 20105949
Speights K. 5 biotech stocks to watch with the coronavirus scare 2020.
Dyall J, Coleman CM, Hart BJ, et al. 2014 Repurposing of
clinically developed drugs for Tteatment of Middle East respiratory
syndrome coronavirus infection Antimicr Agents Chemother 58: